Suppr超能文献

新冠病毒、糖尿病与类固醇:毛霉菌病的恶魔三叉戟

COVID-19, Diabetes and Steroids: The Demonic Trident for Mucormycosis.

作者信息

Bhandari Sudhir, Bhargava Shruti, Samdhani Sunil, Singh Shashank Nath, Sharma Bharat Bhushan, Agarwal Sunita, Sharma Man Prakash, Sharma Srikant, Sharma Vishnu, Kakkar Shivankan, Dube Amitabh, Grover Mohnish

机构信息

Department of Medicine, SMS Medical College, Jaipur, India.

Department of Pathology, SMS Medical College, Jaipur, India.

出版信息

Indian J Otolaryngol Head Neck Surg. 2022 Oct;74(Suppl 2):3469-3472. doi: 10.1007/s12070-021-02883-4. Epub 2021 Oct 4.

Abstract

Coronavirus disease 2019 (COVID-19) has been found to be associated with mucormycosis in few parts of the world, especially India. It is important to look for reasons for this upsurge of cases so that other countries may take proper steps to prevent it. A prospective clinico-demographic study was conducted in SMS Medical College, Jaipur, India from April to May 2021. All patients (235) with COVID associated mucormycosis (CAM) were studied in detail with reference to their diabetic status and steroid intake during treatment of COVID-19. Steroid usage was in 84.3% of patients with methylprednisolone being the most commonly used steroid (66.8%). Majority of the patients had taken steroids for 7-14 days. Diabetes was found in 204 patients and 42.1% of patients were newly diagnosed during/after COVID-19 treatment. The HbA1c levels of diabetic patients ranged from 6.0% to 16.3%. This is perhaps the biggest study in the world shows that the triad of COVID-19, diabetes and steroid usage is a major contributing factor towards mucormycosis. Proper steps should be taken to prevent CAM.

摘要

2019冠状病毒病(COVID-19)在世界上的一些地区,尤其是印度,已被发现与毛霉菌病有关。找出病例激增的原因很重要,这样其他国家才能采取适当措施加以预防。2021年4月至5月,在印度斋浦尔的SMS医学院进行了一项前瞻性临床人口学研究。对所有235例COVID相关毛霉菌病(CAM)患者进行了详细研究,涉及他们在COVID-19治疗期间的糖尿病状况和类固醇摄入量。84.3%的患者使用了类固醇,其中甲泼尼龙是最常用的类固醇(66.8%)。大多数患者使用类固醇的时间为7至14天。204例患者患有糖尿病,42.1%的患者在COVID-19治疗期间/之后被新诊断出糖尿病。糖尿病患者的糖化血红蛋白水平在6.0%至16.3%之间。这可能是世界上最大的一项研究,表明COVID-19、糖尿病和类固醇使用三联征是毛霉菌病的一个主要促成因素。应采取适当措施预防CAM。

相似文献

1
COVID-19, Diabetes and Steroids: The Demonic Trident for Mucormycosis.
Indian J Otolaryngol Head Neck Surg. 2022 Oct;74(Suppl 2):3469-3472. doi: 10.1007/s12070-021-02883-4. Epub 2021 Oct 4.
5
Risk factors for COVID-19 associated mucormycosis in India: A case control study.
Med Mycol. 2022 Jul 8;60(7). doi: 10.1093/mmy/myac044.
6
Higher proinflammatory responses possibly contributing to suppressed cytotoxicity in patients with COVID-19 associated mucormycosis.
Immunobiology. 2023 May;228(3):152384. doi: 10.1016/j.imbio.2023.152384. Epub 2023 Apr 11.
8
Epidemiology, Clinical Profile, and Analysis of Risk Factors in COVID Associated Rhino-orbito-cerebral Mucormycosis Patients - An Observational Study.
Indian J Endocrinol Metab. 2023 Nov-Dec;27(6):519-523. doi: 10.4103/ijem.ijem_372_22. Epub 2024 Jan 11.
9
Mucormycosis in the COVID-19 Environment: A Multifaceted Complication.
Front Cell Infect Microbiol. 2022 Jul 18;12:937481. doi: 10.3389/fcimb.2022.937481. eCollection 2022.
10
Multicenter Epidemiologic Study of Coronavirus Disease-Associated Mucormycosis, India.
Emerg Infect Dis. 2021 Sep;27(9):2349-2359. doi: 10.3201/eid2709.210934. Epub 2021 Jun 4.

引用本文的文献

1
Exploring transfer learning in chest radiographic images within the interplay between COVID-19 and diabetes.
Front Public Health. 2023 Oct 18;11:1297909. doi: 10.3389/fpubh.2023.1297909. eCollection 2023.
2
Clinical Phenotypes of COVID-19 Associated Mucormycosis (CAM): A Comprehensive Review.
Diagnostics (Basel). 2022 Dec 8;12(12):3092. doi: 10.3390/diagnostics12123092.
3
Management of Mucormycosis in Post COVID-19 Patients and Its Outcome in a Tertiary Care Center: Our Experience.
Indian J Otolaryngol Head Neck Surg. 2022 Oct;74(Suppl 2):3344-3351. doi: 10.1007/s12070-022-03197-9. Epub 2022 Oct 15.
4
Mucormycosis in COVID-19 pandemic: study at tertiary hospital in India.
Eur Arch Otorhinolaryngol. 2022 Jun;279(6):3201-3210. doi: 10.1007/s00405-022-07282-1. Epub 2022 Feb 5.

本文引用的文献

1
Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India.
Diabetes Metab Syndr. 2021 Jul-Aug;15(4):102146. doi: 10.1016/j.dsx.2021.05.019. Epub 2021 May 21.
4
Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum.
J Laryngol Otol. 2021 May;135(5):442-447. doi: 10.1017/S0022215121000992. Epub 2021 Apr 8.
5
COVID-19 and orbital mucormycosis.
Indian J Ophthalmol. 2021 Apr;69(4):1002-1004. doi: 10.4103/ijo.IJO_3763_20.
7
Expression of SARS-CoV-2 Entry Factors in the Pancreas of Normal Organ Donors and Individuals with COVID-19.
Cell Metab. 2020 Dec 1;32(6):1041-1051.e6. doi: 10.1016/j.cmet.2020.11.005. Epub 2020 Nov 13.
8
Immunity, endothelial injury and complement-induced coagulopathy in COVID-19.
Nat Rev Nephrol. 2021 Jan;17(1):46-64. doi: 10.1038/s41581-020-00357-4. Epub 2020 Oct 19.
10
Lymphopenia during the COVID-19 infection: What it shows and what can be learned.
Immunol Lett. 2020 Sep;225:31-32. doi: 10.1016/j.imlet.2020.06.013. Epub 2020 Jun 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验